anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Invention herewith described protects a new pharmaceutical form, coated and double coated gastroresistent pills, with diclofenac natrium as an active substance. The peculiarity of formulation is in the film coating from which the initial dosage of active principle is released, while the core is a matrix system on the basis of cellulose derivates of different viscosity which, together with other auxiliary substances, provides for controlled release of diclofenac natrium within 12 to 24 hours, and therewith controls the level of active substance in plasma state. In the case of coated pills during the first hour the quantity of 25 mg is released, i.e. 50 mg of active substance, and the remaining 50 mg are released gradually during 12 to 24 hours. This type of release profile is achieved by application of the procedure of coating the pills with suspension that contains active principle, and carefully chosen high viscosity cellulose derivatives already existing in the core, and provide for lasting release. Peculiarity of gastroresistent pill formulations with controlled release is in the presence of additional coating, which contains co-polymers of metacryle acid which provide specific release of diclofenac natrium in certain part of gastroresistent trackt (proximal part of intestine). Its possible irritating effect to the mucous membrane of the stomach is prevented. Within 3 hours from taking the pill, 25 mg are released, i.e. 50 mg of active substance, and the remaining 50 mg is released gradully within the following 12 to 24 hours.
OBJECTIVE: The presence of cannon A waves, the so called "frog sign", has traditionally been considered diagnostic of atrioventricular nodal re-entrant tachycardia (AVNRT). Nevertheless, it has never been systematically evaluated. The aim of this study is to assess the independent diagnostic utility of cannon A waves in the differential diagnosis of supraventricular tachycardias (SVTs).
METHODS: We prospectively included 100 patients who underwent an electrophysiology (EP) study for SVT. The right jugular venous pulse was recorded during the study. In 61 patients, invasive central venous pressure (CVP) was registered as well. CVP increase is thought to be related with the timing between atria and ventricle depolarization; two groups were prespecified, the short VA interval tachycardias (including typical AVNRT and atrioventricular reciprocating tachycardia (AVRT) mediated by a septal accessory pathway) and the long VA interval tachycardias (including atypical AVNRT and AVRT mediated by a left free wall accessory pathway).
RESULTS: The relationship between cannon A waves and AVNRT did not reach the statistical significance (OR: 3.01; p = .058); On the other hand, it was clearly associated with the final diagnosis of a short VA interval tachycardia (OR: 10.21; p < .001). CVP increase showed an inversely proportional relationship with the VA interval during tachycardia (b = -.020; p < .001). CVP increase was larger in cases of AVNRT (4.0 mmHg vs. 1.2 mmHg; p < .001) and short VA interval tachycardias (3.9 mmHg vs. 1.2 mmHg; p < .001).
CONCLUSION: The presence of cannon A waves is associated with the final diagnosis of short VA interval tachycardias.
In Part A, cohorts of healthy nonsmokers were randomized to either active SBP-9330 or matching placebo. In each cohort a sentinel group of 2 subjects were randomized and dosed ahead of the rest of the cohort. A review of safety data was completed prior to administration of doses to the remainder of the cohort.
Students who score over 110 on the premenstrual syndrome scale and meet the study criteria will be included in the experimental and control groups. Students in this group will not receive training and will be administered the Personal Information Form, PMS Scale, Premenstrual Eating Habits Form, Healthy Lifestyle Behaviors Scale, Emotional Eating Scale, Perceived Stress Scale and Visual Vissual Pain Scale. Data will be collected by face-to-face research method. Survey forms will be filled out by the control group.
The invention provides a preparation method of a memantine hydrochloride sustained-release preparation. According to the present invention, sustained-release pellets are obtained by sustained-release coating of drug-containing pellets containing memantine hydrochloride. The drug-containing pellets are obtained by extrusion spheronization or solution medicine-feeding or suspension medicine-feeding, and are nearly circular in shape. The shape and granularity-controllable drug-containing pellets are subjected to sustained-release coating and the thickness of the film formed by coating can also be controlled. The invention realizes the controllability of the coating film and the spherical pellets, and reproducibility of stability of releasing the memantine hydrochloride is controlled under the circumstance of guaranteeing nonoccurrence of crystal form of memantine hydrochloride. The preparation of the invention can provide sustained release in the form of a single dose within 24 hours. The drug penetrates and diffuses to the release medium through the film pores. Because the size is small, the medicine taking is less susceptible to foods and the efficacy is improved. The production method of the present invention is simple, is suitable for industrial production, and has a great application value.
Previous studies reported that prevalence of thyroid nodules (TN) is increased in patients with insulin resistance (IR) and type 2 diabetes mellitus (T2DM). However, there are no guidelines for the management of TN in this target population. In 2013, the French National Health Insurance reported that thyroid surgery procedures for benign nodules have increased unjustifiably. The impact of such surgery on the patients could be serious, with psychological repercussions and risks of surgical complications and the need of a substitutive lifetime hormonal treatment. The investigators hypothesize that metformin may reduce the need of TN surgery by decreasing benign TN size through a reduction of IR profile. A 2-years multicentric prospective study will be conducted to compare efficacy of metformin versus sitagliptin on benign thyroid nodules size in patients with initial benign thyroid nodules ≥ 2 cm. The percentage of thyroid surgery avoided, IR profile measured by Homeostasis Model Assessment of Insulin Resistance-Index (HOMA-IR-index) and adipokines concentrations will be also collected at inclusion ad at 2 years. The Primary outcome will be the percentage of patients in each group who had at least a 20% decrease in one or more nodules of more than 2 cm at 2 years. Several secondary outcomes will be registered: percentage of thyroid surgery observed in each group at 2 years, number of new TN (≥ 10mm) after 2 years of follow-up , percentage of metabolic syndrome before and after treatment, proportion of subjects with improvement of the HOMA-IR index and adipokine concentrations, plasmatic thyroid-stimulating hormone (TSH), T4 and T3 levels evolution, percentage of insulin like growth factor-1 (IGF-1) and adiponectin receptor expression in thyroid tissues after TN surgery.
Texas Woman's University students from the School of Physical Therapy - Houston campus will be recruited to participate in this study. The participant will be excluded if they have pain in the shoulder on the day of testing, less than 90 degrees of active or passive shoulder abduction, less than 90 degrees of active or passive elbow flexion, have had any previous surgeries or procedures to either shoulder or identify by self-report any reason that they should not perform active external rotation at the shoulder.
XYWAV may impair respiratory drive, especially in patients with compromised respiratory function. In overdoses of oxybate and with illicit use of GHB, life-threatening respiratory depression has been reported [see Overdosage (10)]. 

Increased apnea and reduced oxygenation may occur with XYWAV administration in adult and pediatric patients. A significant increase in the number of central apneas and clinically significant oxygen desaturation may occur in patients with obstructive sleep apnea treated with XYWAV.

In a study assessing the respiratory-depressant effects of Xyrem (same active moiety as XYWAV) at doses up to 9 g per night in 21 adult patients with narcolepsy, no dose-related changes in oxygen saturation were demonstrated in the group as a whole. One of the four patients with preexisting moderate-to-severe sleep apnea had significant worsening of the apnea/hypopnea index during treatment.

In a study assessing the effects of Xyrem 9 g per night in 50 adult patients with obstructive sleep apnea, Xyrem did not increase the severity of sleep‑disordered breathing and did not adversely affect the average duration and severity of oxygen desaturation overall. However, there was a significant increase in the number of central apneas in patients taking Xyrem, and clinically significant oxygen desaturation (≤55%) was measured in three patients (6%) after Xyrem administration, with one patient withdrawing from the study and two continuing after single brief instances of desaturation.

During polysomnographic evaluation (PSG), central sleep apnea and oxygen desaturation were observed in pediatric patients with narcolepsy treated with Xyrem. 

Prescribers should be aware that increased central apneas and clinically relevant oxygen desaturation events have been observed with sodium oxybate administration in adult and pediatric patients.

In clinical trials of Xyrem in 128 adult patients with narcolepsy, two patients had profound CNS depression, which resolved after supportive respiratory intervention. Two other patients discontinued sodium oxybate because of severe difficulty breathing and an increase in obstructive sleep apnea. In two controlled trials assessing PSG measures in adult patients with narcolepsy, 40 of 477 patients were included with a baseline apnea/hypopnea index of 16 to 67 events per hour, indicative of mild to severe sleep-disordered breathing. None of the 40 patients had a clinically significant worsening of respiratory function, as measured by apnea/hypopnea index and pulse oximetry at doses of 4.5 g to 9 g per night.

Prescribers should be aware that sleep-related breathing disorders tend to be more prevalent in obese patients, in men, in postmenopausal women not on hormone replacement therapy, and among patients with narcolepsy.
FIELD: food industry, veterinary. SUBSTANCE: method involves mixing water with condensed subcheese whey, condensed defatted milk (skimmed milk), quinosol, pepsin followed by thermostatic control. Ready product is dried. Pepsin is mixed for two steps: one half of dose is added at component mixing and second one at drying by spraying. Dietetic agent is used for gastroenteric diseases treatment in young stock agricultural animals. EFFECT: improved method of treatment. 2 cl, 1 tbl
PURPOSE: A composition containing stem cell-derived microvesicles for promoting neurogenesis is provided to promote neuron migration and to treat nerve injury. CONSTITUTION: A composition for promoting neurogenesis contains stem cell-derived microvesicles as an active ingredient. The stem cell-derived microvesicle is induced by ischemic stimulation. The stem cell-derived microvesicle is CD105-positive and annexin V-negative microvesicle. The stem cells include induced an induced pluripotent stem cell(iPS), an adult stem cell, an embryonic stem cell, a mesenchymal stem cell, an adipose-derived stem cell, a hematopoietic stem cell, an umbilical cord blood stem cell, or a dedifferentiation stem cell. A pharmaceutical composition for preventing or treating neurodegenerative diseases contains the stem cell-derived microvesicles as an active ingredient.
PURPOSE:A diuretic agent consisting of a complex of albumin with a hydrophobic loop diuretic agent. CONSTITUTION:A diuretic agent obtained by incorporating albumin (obtained by purifying directly a raw material blood plasma) with a hydrophobic loop diuretic agent (hydrophobic organic acid based diuretic agent containing furosemide, ethacrynic acid, bumetamide, etc.) at 1:1-1:5 molar ratio in a suitable solvent, e.g. sodium hydroxide reagent, physiological saline solution or phosphate-buffered saline (PBS) to give a complex, and incorporating the resultant complex therein, and having thermal stabilizing effect on albumin. The heat treatment of this albumin complex can be carried out under given conditions (60 deg.C for 10hr). In the heat treatment, the above-mentioned complex is characterized in that the amount of the given stabilizer can be reduced when the linked diuretic agent, particularly >=3mol, based on the albumin, diuretic agent is present. The administration is carried out using 0.3-1mg/kg expressed in terms of the furosemide by intravenous injection.
The purpose was to investigate relationships of cumulative load and cartilage turnover biomarkers with 2-year changes in cartilage in knee osteoarthritis. From participants with Kellgren-Lawrence (KL) grades of 1 to 3, cartilage thickness and transverse relaxation time (T2) were computed from 24-month (baseline) and 48-month magnetic resonance images. Cumulative load was the interaction term of the Physical Activity Scale for the Elderly (PASE) and body mass index (BMI). Serum cartilage oligomeric matrix protein (COMP) and the nitrated form of type II collagen (Coll2-1 NO2) were collected at baseline. Multiple regressions (adjusted for baseline age, KL grade, cartilage measures, pain, comorbidity) evaluated the relationships of cumulative load and biomarkers with 2-year changes. In 406 participants (63.7 (8.7) years), interactions of biomarkers with cumulative load weakly predicted 2-year cartilage changes: (i) COMP × cumulative load explained medial tibia thickness change (R2 increased 0.062 to 0.087, p < 0.001); (ii) Coll2-1 NO2 × cumulative load explained central medial femoral T2 change (R2 increased 0.177 to 0.210, p < 0.001); and (iii) Coll2-1 NO2 × cumulative load explained lateral tibia T2 change (R2 increased 0.166 to 0.188, p < 0.001). Moderate COMP or Coll2-1 NO2 at baseline appeared protective. High COMP or Coll2-1 NO2, particularly with high BMI and low PASE, associated with worsening cartilage. Moderate serum concentrations of cartilage turnover biomarkers, at high and low physical activity, associated with maintained cartilage outcomes over 2 years. In conclusion, high concentrations of cartilage turnover biomarkers, particularly with high BMI and low physical activity, associated with knee cartilage thinning and increasing T2 over 2 years. Key Points • Higher quality cartilage may be better able to tolerate a larger cumulative load than poor quality cartilage. • Among participants enrolled in the Osteoarthritis Initiative Biomarkers Consortium Project, a representation of cumulative load exposure and its interaction with cartilage turnover biomarkers were weakly related with 2-year change in knee cartilage. • These findings suggest that cartilage turnover is a factor that modifies the relationship between loading exposure and cartilage loss in knee OA.
This injury has traditionally been treated in a plaster cast applied to the leg for a period of 10 weeks which allows the tendon to heal, or by an operation to repair the tendon. Research undertaken in the investigators department has shown that patients treated with surgery or with a plaster had similar chance of re-rupture of the tendon after treatment and gain a similar recovery. The investigators therefore now manage these injuries in a plaster.

More recently, further research has shown that a new type of non-surgical rehabilitation programme, which is quicker than the traditional non-surgical programme, gave a tendon re-rupture rate that was similar to that after surgical treatment. This new rehabilitation programme uses a walking boot fitted with a heel-raise (instead of the traditional plaster). The potential benefit of this quicker rehabilitation programme is that it allows the patient to put weight through the leg immediately, whereas patients treated with the traditional plaster cast non-surgical treatment cannot weight bear (this means that they are kept non-weightbearing and therefore have to use crutches) for the first 8 weeks. The time spent in the walking boot in this new, quicker rehabilitation programme is 8 weeks while that spent in plaster is 10 weeks. This new non-surgical, quicker rehabilitation programme is referred to as the accelerated non-surgical programme hereafter. There are no known increased risks with the accelerated rehabilitation programme.
Allogeneic stem cell transplantation (SCT) offers the hope of cure for a wide variety of hematologic malignancies. Mature donor T-cells play a critical role in the success or failure of this procedure. A subset of donor T-cells mediates graft-versus-host disease (GvHD). Other subsets provide the foundation for immune recovery. Pan-depletion of mature donor T-cells is an obligate step in haploidentical allogeneic stem cell transplantation. Without this step, the recipient would succumb to lethal acute GVHD. We have had extensive experience with in-vivo donor (and recipient) T-cell depletion using alemtuzumab as part of the bone marrow conditioning regimen. We and others have also used anti-thymocyte globulin for the same purpose. Pan-depletion of T-cells eliminates GvHD but significantly increases the risks of tumor relapse and opportunistic infections. A delayed donor lymphocyte infusion augments immune recovery and the graft versus tumor response, but it comes at the risk of inducing lethal GvHD. This is particularly problematic when the donor and recipient are HLA-discordant. Thus the major challenge in allogeneic stem cell transplantation is determining how to maximally exploit the beneficial effects mediated by T-cells without causing GvHD. This challenge could be overcome by selectively depleting the population of donor T-cells responsible for eliciting the GvHD response. We have been interested in selecting T-cells based on their naïve or memory phenotype to understand the contribution of each of these cells to the pathogenesis of GvHD. Naïve T-cells (CD62L+ or CD45RA+) are T-cells that have not encountered antigens specific for their T-cell receptor. Memory T-cells (CD62L- or CD62L+ or CD45RA-) are T-cells that have previously been exposed to their corresponding cognate antigens. If a donor has not encountered host alloantigens, GvHD-inducing host-reactive T-cells should be contained in the naïve T-cell compartment. In contrast, all the memory phenotype cells should not recognize host alloantigens. If this hypothesis is correct as suggested by several published studies, CD62L- T-cells, which are devoid of naïve T-cells and represent a subset of memory T-cells, should not be able to induce GvHD. The study hypothesis is depletion of naïve T-cells from the donor lymphocyte inoculum will abrogate GVHD while providing immunocompetent memory T-cells to affect an anti-infection and a graft versus tumor response. In this study, we will determine the maximum tolerated dose of a naïve T-cell depleted donor lymphocyte infusion given to patients following HLA-matched allogeneic stem cell transplantation. We will assess the GVHD-inducing potential of this donor lymphocyte infusion and further monitor the impact that this DLI will have on post-transplant immune recovery.
PURPOSE:A germanium releasing material, prepared by introducing a medicinal herb for a warm bath smeared with fine particles of an inorganic or organic germanium into a container having the permeability, and having the ability to cure various diseases caused by oxygen deficiency effectively. CONSTITUTION:Fine particles of an inorganic or organic germanium e.g. germanium oxide, are smeared on a medicinal herb for a warm bath, and the resultant smeared herb is then introduced into a container having the permeability, e.g. a cloth bag, to give a germanium releasing material. The resultant germanium releasing material is combination of a germanium compound with the medicinal herb and inexpensive compared with the natural ore, and has no disadvantage that the mineral cmponent will dissolve out to the warm water to damage a vessel or bath- tub on dipping in the bathtub. On the other hand, the component of the medicinal berb disslves out to the warm water to enhance the health promoting effect synergistically.
The is a randomized control study for newly-diagnosed myeloma patients 18-65 year old. Newly-diagnosed myeloma patient enrolled will receive 4 cycles of velcade and Dexamethasone as front-line induction therapy. All patients finished the induction therapy will be randomized into standard group and the study group. All patients will mobilized by cyclophosphamide with G-CSF to collect a target of 2x106 CD34+/kg and then undergo autologous stem cell transplantation. For standard group, patients will receive single auto-SCT with standard conditioning of melphalan 200mg/m2. The patients in the study group will receive single auto-SCT with conditioning of melphalan 200mg/m2 added with 4 dose of velcade at 1.0mg/m2 during the transplantation procedure and then followed by 3 more cycles of velcade alone as consolidation.
Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
PCT No. PCT/EP94/00286 Sec. 371 Date Sep. 15, 1995 Sec. 102(e) Date Sep. 15, 1995 PCT Filed Feb. 2, 1994 PCT Pub. No. WO94/18325 PCT Pub. Date Aug. 18, 1994The invention relates to tumor necrosis factor muteins characterized in that the TNF- alpha  amino acid sequence is mutated, or deleted totally or partially, in the region containing position 101 to 116 in such a way that: either the lectin-like activity is reduced with respect to TNF- alpha , or the toxic activity is reduced with respect to TNF- alpha ; and providing that said muteins have largely retained the tumoricidal activity of TNF- alpha ; and with said muteins possibly containing in their peptidic chain additional modifications consisting of substitutions and/or deletions and/or additions of one or several amino acid residues, and with said muteins being characterized in that they have retained the aforementioned activities; or a pharmaceutically acceptable salt thereof.
A dentrifrice compsn. comprises as antibacterial agent 1,6-di-(p-chlorophenyl-biguanido)hexane (otherwise chlorohexidine) or its salt and an excipient which contains >=1 foaming agent and/or >=1 sweetening agent compatible with the antibacterial agent. The compatibility is determined by micro-biological test to ensure that the minimum inhibiting concn. of the agent plus additive(s) is at least equal to the minimum inhibiting concn. of the agent or its own. The compsn. is used in tooth pastes etc to remove or present the formation of dental plaque. The compsn. and testing procedure ensures that an effective amt. of agent is present unlike previous compsns. in which it has been found that other additives, esp. those above, reduce the efficicacy of the agent.
A method determines the most effective motivator at inducing a user to engage in a digital mental health intervention. The user is exposed to a first motivator that prompts the user to perform the intervention. The motivator can be a video, audio tape, textual explanation or quiz-like game. Intervention and motivator parameters are monitored to assess user engagement both with the first motivator and in performing the intervention. An intervention delivery model is personalized to the user based on both parameters. The intervention delivery model is used to determine the efficacy of the first motivator at motivating the user to perform the intervention. The intervention and motivator parameters are compared to an intervention engagement threshold and a motivator engagement threshold. If either or both parameters are below the corresponding threshold, the intervention delivery model is used to select a second motivator. The user is then exposed to the second motivator.